keyword
MENU ▼
Read by QxMD icon Read
search

non radiographic axial spondyloarthritis

keyword
https://www.readbyqxmd.com/read/29148402/incidence-and-prevalence-of-axial-spondyloarthritis-methodologic-challenges-and-gaps-in-the-literature
#1
Rhonda Bohn, Maureen Cooney, Atul Deodhar, Jeffrey R Curtis, Amanda Golembesky
OBJECTIVES: The incidence and prevalence of axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS) and non-radiographic (nr-)axSpA, have been investigated in multiple populations, though there is a paucity of population-level data. Here, we identify population-based studies in AS and nr-axSpA, and describe the methodologic challenges in conducting these, outlining potential reasons for disparate incidence and prevalence estimates. METHODS: PubMed and Embase were searched for population-based studies providing incidence and prevalence rates, published in English from 1 Jan 2000-30 Jun 2015...
November 14, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28970212/modification-of-structural-lesions-on-mri-of-the-sacroiliac-joints-by-etanercept-in-the-embark-trial-a-12-week-randomised-placebo-controlled-trial-in-patients-with-non-radiographic-axial-spondyloarthritis
#2
Walter P Maksymowych, Stephanie Wichuk, Maxime Dougados, Heather E Jones, Ron Pedersen, Annette Szumski, Lisa Marshall, Jack F Bukowski, Robert G Lambert
OBJECTIVE: To evaluate the impact on structural lesions observed on MRI in the sacroiliac joints (SIJ) at 12 weeks in patients with non-radiographic axial spondyloarthritis (nr-axSpA) receiving etanercept or placebo in EMBARK (Effect of Etanercept on Symptoms and Objective Inflammation in nr-axSpA, a 104 week study). METHODS: Patients were randomised to double-blind etanercept 50 mg/week or placebo for 12 weeks. Structural lesions at baseline and 12 weeks were scored by two independent readers using the Spondyloarthritis Research Consortium of Canada (SPARCC) SIJ structural score (SSS) on T1-weighted MRI...
September 29, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28968885/patients-with-fibromyalgia-rarely-fulfil-classification-criteria-for-axial-spondyloarthritis
#3
Xenofon Baraliakos, Andrea Regel, Uta Kiltz, Hans-Jürgen Menne, Friedrich Dybowski, Manfred Igelmann, Ludwig Kalthoff, Dietmar Krause, Ertan Saracbasi-Zender, Elmar Schmitz-Bortz, Jürgen Braun
Background: The Assessments of Spondyloarthritis international Society (ASAS) classification criteria for axial spondyloarthritis (axSpA) have been criticized because of insufficient differentiation towards FM. The aim of this study was to compare the performance of currently used classification criteria in patients diagnosed with axSpA or FM. Methods: Patients were prospectively included if diagnosed with axSpA or FM by the treating rheumatologist and evaluated by an independent examiner for fulfilment of the classification criteria for axSpA (ASAS criteria) and/or FM (1990 ACR classification and 2010 ACR diagnostic criteria)...
September 6, 2017: Rheumatology
https://www.readbyqxmd.com/read/28957558/analysis-of-dedicated-sacroiliac-views-to-improve-reliability-of-conventional-pelvic-radiographs
#4
COMPARATIVE STUDY
Ahmed Omar, Ismail Sari, Mohamed Bedaiwi, David Salonen, Nigil Haroon, Robert D Inman
Objective: To compare the antero-posterior (AP) pelvis view with the Ferguson view of the SI joint in order to resolve whether one modality has a clear advantage for grading of sacroiliitis. Methods: One hundred and nine patients fulfilling Assessment of SpondyloArthritis international Society (ASAS) criteria for axial spondyloarthritis who had AP pelvis and Ferguson views on the same day were identified from an axial spondyloarthritis clinic registry. Two rheumatologists independently scored the AP pelvis and Ferguson views according to modified New York (NY) criteria...
October 1, 2017: Rheumatology
https://www.readbyqxmd.com/read/28940172/gp2015-an-etanercept-biosimilar
#5
Emma D Deeks
GP2015 is the second biosimilar of the reference p75 TNF receptor-Fc fusion protein etanercept. It is approved for use in all indications for which reference etanercept is approved, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis and paediatric plaque psoriasis. GP2015 has similar physiochemical and pharmacodynamic properties to those of reference etanercept, and the pharmacokinetic biosimilarity of the agents has been shown in healthy volunteers...
September 23, 2017: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/28938006/association-between-circulating-mirnas-and-spinal-involvement-in-patients-with-axial-spondyloarthritis
#6
Klára Prajzlerová, Kristýna Grobelná, Markéta Hušáková, Šárka Forejtová, Astrid Jüngel, Steffen Gay, Jiří Vencovský, Karel Pavelka, Ladislav Šenolt, Mária Filková
OBJECTIVES: Dysregulation of miRNAs and their target genes contributes to the pathophysiology of autoimmune diseases. Circulating miRNAs may serve as diagnostic/prognostic biomarkers. We aimed to investigate the association between circulating miRNAs, disease activity and spinal involvement in patients with axial spondyloarthritis (AxSpA). METHODS: Total RNA was isolated from the plasma of patients with non-radiographic (nr)AxSpA, patients with ankylosing spondylitis (AS) and healthy controls (HC) via phenol-chloroform extraction...
2017: PloS One
https://www.readbyqxmd.com/read/28933136/coexistence-of-spondyloarthritis-and-joint-hypermobility-syndrome-rare-or-unknown-association
#7
J B Pinto Carneiro, T Pinto de Souza, T M L Antunes de Oliveira, S L Euzébio Ribeiro
We report two cases of siblings presenting coexisting non-radiographic axial spondyloartrhritis and joint hypermobility syndrome, complaining of back pain with morning stiffness, enthesitis, peripheral arthralgia, high erythrocyte sedimentation rate and C-reactive protein level and positive HLA-B27. The association of these two conditions is rare, but especially interesting in view of their contrasting features, one causing axial skeleton stiffness, the other a wider range of peripheral joint movements. Coexistence of these two opposite disorders causes confusion in diagnosis and management, resulting in lower quality of life for patients, as they are in pain from the early stages...
September 21, 2017: Reumatismo
https://www.readbyqxmd.com/read/28917996/poor-efficacy-of-tnf-inhibitors-in-non-radiographic-axial-spondyloarthritis-in-the-absence-of-objective-signs-a-bicentric-retrospective-study
#8
Céline Vidal, Cédric Lukas, Bernard Combe, Francis Berenbaum, Yves Marie Pers, Christian Jorgensen, Jérémie Sellam, Jacques Morel
OBJECTIVE: To compare BASDAI 50 response rate to TNFi in axial spondyloarthritis (axSpA) depending on the presence or not of objective signs of axSpA and to look for predictive factors of TNFi efficacy. METHODS: Patients diagnosed with axSpA according to ASAS criteria "clinical arm" and treated between January 2001 and September 2015 with TNFi were included. First group included patients with at least one objective sign such as arthritis, dactylitis, enthesitis, uveitis, inflammatory bowel disease, elevated C-reactive protein or radiological sacroiliitis, and second group included non-radiographic axSpA (nr-axSpA) patients without any objective sign corresponding to patients with inflammatory back pain and either a good response to NSAID or a SpA family history...
September 13, 2017: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/28894079/portuguese-recommendations-for-the-use-of-biological-therapies-in-patients-with-axial-spondyloarthritis-2016-update
#9
Pedro Machado, Marcos Cerqueira, Pedro Ávila-Ribeiro, Renata Aguiar, Alexandra Bernardo, Alexandre Sepriano, Ana Águeda, Ana Cordeiro, Ana Raposo, Ana M Rodrigues, Anabela Barcelos, Armando Malcata, Carina Lopes, Cláudia C Vaz, Dolores Nour, Fátima Godinho, Fernando Alvarenga, Fernando Pimentel-Santos, Helena Canhão, Helena Santos, Inês Cunha, Joana Sousa Neves, João Eurico Fonseca, João Lagoas Gomes, José Tavares-Costa, Lúcia Costa, Luís Cunha-Miranda, Luís Maurício, Margarida Cruz, Maria Carmo Afonso, Maria José Santos, Miguel Bernardes, Paula Valente, Ricardo Figueira, Sofia Pimenta, Sofia Ramiro, Teresa Pedrosa, Tiago Afonso Costa, Elsa Vieira-Sousa
OBJECTIVE: To update the recommendations for the treatment of axial spondyloarthritis (axSpA) with biological therapies, endorsed by the Portuguese Society of Rheumatology. METHODS: These treatment recommendations were formulated by Portuguese rheumatologists based on literature evidence and consensus opinion. At a national meeting, the 7 recommendations included in this document were discussed and updated. A draft of the full text of the recommendations was then circulated and suggestions were incorporated...
July 2017: Acta Reumatológica Portuguesa
https://www.readbyqxmd.com/read/28860446/translation-and-cross-cultural-adaptation-of-the-asas-health-index-and-asas-environmental-factors-item-set-into-european-portuguese-language
#10
Eduardo B Cruz, Sofia Ramiro, Pedro Machado, Sandra Sousa, Renata Aguiar, Alexandre Sepriano, Santiago Rodrigues Manica, Uta Kiltz, Jaime C Branco, Fernando M Pimentel-Santos
OBJECTIVE: There is a lack of outcome measures to assess the impact of axial spondyloarthritis (axSpA) on health, function and quality of life. The Assessment of SpondyloArthritis International Society (ASAS) group developed the ASAS Health Index (ASAS-HI) and the ASAS Environmental Factors Item Set (ASAS-EF) to measure functioning and health across all aspects of health that are typically affected and relevant for patients with axSpA, based on the International Classification of Functioning, Disability and Health (ICF)...
July 2017: Acta Reumatológica Portuguesa
https://www.readbyqxmd.com/read/28856518/changes-of-patient-reported-outcomes-and-protein-fingerprint-biomarkers-after-exercise-therapy-for-axial-spondyloarthritis
#11
Marketa Husakova, Anne Sofie Siebuhr, Karel Pavelka, Maja Spiritovic, Anne-Christine Bay-Jensen, Andrea Levitova
The objective of this study was to investigate the patient-reported outcomes (PROs) and matrix metalloproteinase (MMP) derived extracellular matrix (ECM) biomarkers in non-radiographic (nr)-axial spondyloarthritis (axSpA) and radiographic (r)-axSpA after exercise intervention. Forty-six axSpA patients with stable disease and treatment underwent 24 weeks long exercise intervention. The clinical and laboratory assessments were performed at baseline and at follow-up. The PROs included evaluation of patient's global disease activity (PGDA), disease activity (DA7), pain (PAIN7) and fatigue during last week and quality of life questionnaires...
August 30, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28698330/clinical-characteristics-of-importance-to-outcome-in-patients-with-axial-spondyloarthritis-protocol-for-a-prospective-descriptive-and-exploratory-cohort-study
#12
Rikke Asmussen Andreasen, Lars Erik Kristensen, Torkell Ellingsen, Robin Christensen, Xenofon Baraliakos, Jimmi Wied, Claus Aalykke, Thomas Ulstrup, Berit Schiøttz-Christensen, Hans Christian Horn, Amir Emamifar, Bent Duerlund, Lars Fischer, Inger Marie Jensen Hansen
INTRODUCTION: Spondyloarthritis (SpA) is a heterogeneous spectrum of rheumatic diseases with either predominantly axial inflammatory symptoms of the spine and sacroiliac joints or predominantly peripheral arthritis. The two main entities of axial SpA (axSpA) are ankylosing spondylitis or non-radiographic axSpA (nr-axSpA). Tumour necrosis factor-α inhibitors have revolutionised the treatment of patients with axSpA who failed to respond to non-steroidal anti-inflammatory drugs and physical therapy...
July 10, 2017: BMJ Open
https://www.readbyqxmd.com/read/28684556/sacroiliac-radiographic-progression-in-recent-onset-axial-spondyloarthritis-the-5-year-data-of-the-desir-cohort
#13
MULTICENTER STUDY
Maxime Dougados, Alexandre Sepriano, Anna Molto, Miranda van Lunteren, Sofia Ramiro, Manouk de Hooge, Rosaline van den Berg, Victoria Navarro Compan, Christophe Demattei, Robert Landewé, Désirée van der Heijde
OBJECTIVE: To estimate sacroiliac joint radiographic (X-SIJ) progression in patients with axial spondyloarthritis (axSpA) and to evaluate the effects of inflammation on MRI (MRI-SIJ) on X-SIJ progression. METHODS: X-SIJ and MRI-SIJ at baseline and after 2 and 5 years in patients with recent onset axSpA from the DESIR cohort were scored by three central readers. Progression was defined as (1) the shift from non-radiographic (nr) to radiographic (r) sacroiliitis (by modified New York (mNY) criteria) or alternative criteria, (2) a change of at least one grade or (3) a change of at least one grade but ignoring a change from grade 0 to 1...
November 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28682112/etanercept-for-treating-axial-spondyloarthritis
#14
Xavier Guillot, Clément Prati, Maxime Sondag, Daniel Wendling
Axial spondyloarthritis is an inflammatory rheumatic disease causing back pain, functional impairment and potential ankylosis in the advanced stage. In this context, TNF blockers have been a major therapeutic advance. Etanercept is a soluble recombinant TNF receptor fusion protein in this vain. Areas covered: The aim of this review is to summarize the current published data concerning the efficacy and tolerance of etanercept in axial spondyloarthrits. The authors performed a systematic review on PubMed, using 'etanercept' and 'spondyloarthritis', 'axial spondyloarthritis' or 'ankylosing spondylitis' keywords...
September 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28631696/-ankylosing-spondylitis-and-non-radiographic-axial-spondyloarthritis-two-stages-of-disease
#15
D G Rumyantseva, T V Dubinina, A B Demina, O A Rumyantseva, E M Agafonova, A V Smirnov, Sh F Erdes
AIM: To compare the clinical manifestations of ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nrAxSpA). SUBJECTS AND METHODS: A Moscow early spondyloarthritis cohort has now included 132 patients with axial spondyloarthritis, of whom 69 patients who have been followed up at least 12 months are to be involved in a preliminary analysis. The mean age at the time of inclusion in the study was 28.1±5.5 years; the mean disease duration was 24...
2017: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/28623950/work-outcome-in-yet-undiagnosed-patients-with-non-radiographic-axial-spondyloarthritis-and-ankylosing-spondylitis-results-of-a-cross-sectional-study-among-patients-with-chronic-low-back-pain
#16
Lonneke van Hoeven, Annelies E R C H Boonen, Johanna M W Hazes, Angelique E A M Weel
BACKGROUND: To understand the impact of yet undiagnosed non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) on work outcomes in a cohort of patients with long-lasting chronic low back pain (CLBP). METHODS: Data were used from a primary care CLBP cohort that was established to understand the prevalence of nr-axSpA and AS. Clinical characteristics comprised measures of back pain (visual analogue scale), inflammation (C-reactive protein) and physical functioning (Roland Morris Disability Questionnaire (RMDQ))...
June 17, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28612180/immunogenicity-of-biologics-in-chronic-inflammatory-diseases-a-systematic-review
#17
REVIEW
Vibeke Strand, Alejandro Balsa, Jamal Al-Saleh, Leonor Barile-Fabris, Takahiko Horiuchi, Tsutomu Takeuchi, Sadiq Lula, Charles Hawes, Blerina Kola, Lisa Marshall
OBJECTIVES: A systematic review was conducted to explore the immunogenicity of biologic agents across inflammatory diseases and its potential impact on efficacy/safety. METHODS: Literature searches were conducted through November 2016 to identify controlled and observational studies of biologics/biosimilars administered for treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis (nr-axSpA), psoriasis (Ps), Crohn's disease, and ulcerative colitis...
June 13, 2017: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/28587658/mri-evidence-of-structural-changes-in-the-sacroiliac-joints-of-patients-with-non-radiographic-axial-spondyloarthritis-even-in-the-absence-of-mri-inflammation
#18
Walter P Maksymowych, Stephanie Wichuk, Maxime Dougados, Heather Jones, Annette Szumski, Jack F Bukowski, Lisa Marshall, Robert G Lambert
BACKGROUND: Studies have shown that structural lesions may be present in patients with non-radiographic axial spondyloarthritis (nr-axSpA). However, the relevance of structural lesions in these patients is unclear, particularly without signs of inflammation on magnetic resonance imaging (MRI). We assessed the presence of structural lesions at baseline on MRI in the sacroiliac joints (SIJ) of patients with nr-axSpA with and without SIJ inflammation on MRI. METHODS: Bone marrow edema (BME) was assessed on short tau inversion recovery (STIR) scans from 185 patients with nr-axSpA, by two independent readers at baseline using the Spondyloarthritis Research Consortium of Canada (SPARCC) score...
June 6, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28530020/golimumab-a-review-in-inflammatory-arthritis
#19
James E Frampton
Golimumab (Simponi(®)), a fully human monoclonal antibody against tumour necrosis factor-alpha (TNFα), is given once monthly by subcutaneous injection. In the EU, golimumab is approved as monotherapy and/or in combination with methotrexate for the treatment of inflammatory arthritis, including rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis [comprising ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA)] in adults, and polyarticular juvenile idiopathic arthritis (pJIA) in children...
June 2017: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/28498975/sustained-efficacy-safety-and-patient-reported-outcomes-of-certolizumab-pegol-in-axial-spondyloarthritis-4-year-outcomes-from-rapid-axspa
#20
RANDOMIZED CONTROLLED TRIAL
Désirée van der Heijde, Maxime Dougados, Robert Landewé, Joachim Sieper, Walter P Maksymowych, Martin Rudwaleit, Filip Van den Bosch, Jürgen Braun, Philip J Mease, Alan J Kivitz, Jessica Walsh, Owen Davies, Lars Bauer, Bengt Hoepken, Luke Peterson, Atul Deodhar
Objective: The aim was to assess the long-term safety and efficacy of certolizumab pegol over 4 years of continuous treatment in patients with axial spondyloarthritis (axSpA), including both AS and non-radiographic (nr-) axSpA. Methods: RAPID-axSpA was a phase 3 randomized trial, double blind and placebo controlled to week 24, dose blind to week 48 and open label to week 204. Patients had a clinical diagnosis of axSpA, meeting Assessment of SpondyloArthritis international Society (ASAS) criteria, and had active disease...
September 1, 2017: Rheumatology
keyword
keyword
111757
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"